| Stereochemistry | ACHIRAL |
| Molecular Formula | Te.Zn |
| Molecular Weight | 193.01 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Zn++].[Te--]
InChI
InChIKey=DUBYYKAZPKUEPE-UHFFFAOYSA-N
InChI=1S/Te.Zn/q-2;+2
| Molecular Formula | HTe |
| Molecular Weight | 128.61 |
| Charge | -1 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Zn |
| Molecular Weight | 65.409 |
| Charge | 2 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Zinc telluride is a binary chemical compound with the formula ZnTe. Zinc telluride (ZnTe) is a wide-band-gap II–VI semiconductor (E g=2.25 eV at 300 K) crystallizing in the cubic, zinc-blende structure. This material is promising for application as a purely green light-emitting diode. As Zinc telluride can be easily doped, and for this reason it is one of the more common semiconducting materials used in optoelectronics. Zinc telluride finds applications in the following:
LEDs and laser diodes
Solar cells
Tetrahertz imaging
Electro-optic detector
Holographic interferometry
Laser optical phase conjugation devices.
Gold–zinc telluride (Au–ZnTe) core–shell nanoparticles were synthesized to support surface modifications for enhanced drug delivery in cancer therapeutics.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Patents
Sample Use Guides
Rats: Acute in vivo exposure studies using low (50 ug/ ml), intermediate (500 ug/ml) and high (1500 ug/ml) concentrations of the Au–ZnTe (Gold–zinc telluride) particles were used to investigate histopathological effects in rats. Au–ZnTe core–shell nanoparticles
were filtered, weighed, resuspended in PBS and prepared
for administration to the rats by intraperitoneal (IP)
injection.
Route of Administration:
Intraperitoneal
PHA-stimulated and non-stimulated human PBMCs were
exposed to various concentrations of Au–ZnTe (Gold–zinc telluride) core–shell nanoparticles (50, 25, 12.5, 6.25, 3.125, 1.5, 0.78, 0.39, 0.19 and
0.09 ug/ml) for 72 hours to simulate an in vitro immune response. Exposure to Au–ZnTe nanoparticles at concentrations below 3.125 ug/ml did not
induce a dose-dependent reduction in the cell viability of the
PHA-treated and non-stimulated PBMCs. The viability of the
cells was moderately low (80–95% viability) compared with
their corresponding untreated controls. There was a
clear dose-dependent reduction in the cell viability of the PHA stimulated
and non-stimulated PBMC cells exposed to 6.25 ug/ml or higher concentrations of the nanoparticles.